Hostname: page-component-745bb68f8f-b95js Total loading time: 0 Render date: 2025-01-12T11:28:16.614Z Has data issue: false hasContentIssue false
  • English
  • Français

The Treatment of Neuroleptic Malignant Syndrome are Dantrolene and Bromocriptine Useful Adjuncts to Supportive Care?

Published online by Cambridge University Press:  02 January 2018

Patricia I. Rosebush ,
Thomas Stewart  and
Michael F. Mazurek
Patricia I. Rosebush*
Affiliation:
Department of Psychiatry, McMaster University Medical Centre, Hamilton, Ontario, Canada L8N 3ZS
Thomas Stewart
Affiliation:
Department of Psychiatry, Beth Israel Hospital, Harvard University, Boston, Massachusetts, USA
Michael F. Mazurek
Affiliation:
Division of Neurology, Departments of Medicine and Biomedical Sciences, McMaster University Medical Centre, Hamilton, Ontario
*
∗Correspondence
Get access Rights & Permissions [Opens in a new window]

Abstract

In a prospective study of 20 patients with NMS, those who received dantrolene (2 patients) or bromocriptine (2 patients) or both (4 patients) tended to have a more prolonged course of illness and a greater incidence of sequelae than those treated with supportive care alone. These results do not indicate a useful role for dantrolene or bromocriptine in the treatment of NMS.

Type
Brief Reports
Information
The British Journal of Psychiatry , Volume 159 , Issue 5 , November 1991 , pp. 709 - 712
Copyright
Copyright © 1991 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Davis, J. M. (1976) Comparative doses and costs of antipsychotic medication. Archives of General Psychiatry, 33, 858–861.Google Scholar
Grubbs, F. E. (1969) Procedures for detecting outlying observations in samples. Technometrics, 11, 1–22.CrossRefGoogle Scholar
Rosebush, P. & Stewart, T. (1989) A prospective analysis of 24 episodes of neuroleptic malignant syndrome. American Journal of Psychiatry, 146, 719–725.Google Scholar
Rosenberg, M. & Green, M. (1989) Neuroleptic malignant syndrome: review of response to therapy. Archives of Internal Medicine, 149, 1927–1931.CrossRefGoogle ScholarPubMed
Shalev, A., Hermesh, H. & Munitz, H. (1988) The role of external heat load triggering the neuroleptic malignant syndrome. American Journal of Psychiatry, 145, 110–111.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.